Reaction

Enthesopathy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,557 reports · 93 co-occurring drugs

As of the last recalculation, Enthesopathy appears in 1,557 FAERS reports alongside 93 co-occurring drug terms. The strongest observed disproportionality signal is DIMENHYDRINATE (PRR 286.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dimenhydrinate	199	286.1	291.5
Febuxostat Tablets 40 Mg	187	279.2	284.5
Febuxostat Tablets 80 Mg	187	279.2	284.5
Febuxostat	247	234.0	237.5
Colchicine	245	147.4	148.8
Sulfasalazine	478	117.4	118.1
Adalimumab-Fkjp	309	111.0	111.8
Adalimumab-Aaty	307	107.8	108.5
Ibuprofen And Diphenhydramine Citrate	160	102.3	103.0
Adalimumab-Adaz	318	101.0	101.6
Dexlansoprazole	200	73.4	73.8
Leflunomide	397	67.7	68.0
Golimumab	332	65.5	65.8
Secukinumab	451	52.2	52.3
Naproxen	249	50.3	50.4
Acetaminophen And Codeine	41	46.2	46.3
Certolizumab Pegol	314	44.6	44.7
Ustekinumab	271	42.6	42.8
Apremilast	359	42.3	42.4
Methotrexate Sodium	781	42.1	42.2
Risedronate Sodium	88	40.1	40.2
Hydroxychloroquine	193	39.3	39.4
Methotrexate	684	38.0	38.0
Infliximab	427	35.6	35.7
Alendronate Sodium	228	35.2	35.3
Methylprednisolone Acetate	20	33.8	33.9
Hydroxychloroquine Sulfate	193	32.2	32.3
Celecoxib	255	30.8	30.8
Abatacept	262	30.2	30.3
Naproxen Sodium	256	28.5	28.5
Desoximetasone	35	25.1	25.1
Diphenhydramine Hydrochloride Capsule, Liquid Filled	39	25.0	25.0
Folic Acid	356	24.4	24.5
Tocilizumab	180	23.7	23.8
Ibuprofen Capsule	286	23.3	23.3
Ibuprofen Tablet, Film Coated	286	23.3	23.3
Ibupfrofen	286	23.3	23.3
Ibuprofen Tablets Usp, 200Mg	286	23.3	23.3
Ibuprofen Oral	286	23.2	23.3
Ibuprofen Capsules 200 Mg	286	23.2	23.3
Ibuprofen 200 Mg	286	23.2	23.3
Ibuprofen 200Mg	286	23.2	23.3
Mometasone	31	23.0	23.1
Infliximab-Dyyb	48	22.6	22.7
Indomethacin	21	21.5	21.5
Cyclosporine	158	21.0	21.0
Ibuprofen	334	20.7	20.7
Ixekizumab	55	20.6	20.6
Adalimumab	652	20.5	20.5
Oxycodone	241	20.2	20.2
Tofacitinib Citrate	19	19.6	19.6
Meperidine Hydrochloride	13	19.0	19.0
Diphenhydramine Hydrochloride	205	18.9	18.9
Amitriptyline Hydrochloride	22	17.0	17.0
Tofacitinib	203	16.8	16.8
Etanercept	502	16.1	16.1
Meloxicam	67	16.1	16.1
Diclofenac	97	16.0	16.0
Clobetasol Propionate Ointment Usp, 0.05%	12	15.7	15.7
Clobetasol Propionate	12	15.6	15.6
Azathioprine	94	15.1	15.1
Esomeprazole Magnesium Capsule, Delayed Release	15	13.9	14.0
Esomeprazole Magnesium Delayed Release Capsules	15	13.9	14.0
Esomeprazole Magnesium Dihydrate	15	13.9	13.9
Alendronate Sodium Tablet	19	13.9	13.9
Rabeprazole	22	13.4	13.5
Calcium Gluconate	12	13.4	13.4
Rituximab	187	13.3	13.3
Cefuroxime	11	12.9	13.0
Lamivudine Oral	23	12.3	12.3
Cannabidiol	20	11.6	11.6
Voriconazole Injection	18	11.2	11.2
Diclofenac Potassium, Film Coated	7	11.2	11.2
Diclofenac Potassium Tablets	7	11.2	11.2
Diclofenac Sodium	117	11.2	11.2
Mometasone Furoate	31	10.1	10.1
Oxycodone Hydrochloride	150	10.1	10.1
Lamivudine	23	10.1	10.1
Rabeprazole Sodium	20	9.9	9.9
Baclofen	61	9.8	9.8
Nitrofurantoin	12	9.8	9.8
Nitrofurantoin (Monohydrate/Macrocrystals)	12	9.7	9.7
Diclofenac Potassium	7	8.7	8.7
Fesoterodine Fumarate	7	8.7	8.7
Baricitinib	6	8.3	8.4
Voriconazole	18	8.0	8.0
Linagliptin	10	7.4	7.4
Rifaximin	11	7.1	7.1
Naproxen Sodium Tablet, Coated	7	6.9	6.9
Naproxen Sodium, Coated Tablets	7	6.9	6.9
Naproxen Sodium 220Mg	7	6.9	6.9
Remdesivir	6	6.0	6.0
Guselkumab	9	3.4	3.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.